Email Pfizer is facing a showdown after a $1.5 billion bid to revive the company’s post-Covid share plunge took a “highly inappropriate, flagrantly unethical” twist.
Want to change how you receive these emails? Manage your newsletter preferences or unsubscribe from this newsletter. Sent by News Pty Limited, 2 Holt Street, Surry Hills, NSW 2010